Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections.

Antimicrobial Agents and Chemotherapy
W R BowieD W Megran

Abstract

Men and women with suspected or proven genital infections caused by Chlamydia trachomatis were enrolled in a double-blind study to evaluate the efficacy and tolerability of fleroxacin. Patients received either 400, 600, or 800 mg once daily for 7 days and were monitored approximately 2, 4, and 7 weeks after initiation of therapy. In men monitored for at least 6 weeks or until failure of the therapy, fleroxacin failed to eradicate C. trachomatis in three of eight on the 400-mg regimen, in one of four on the 600-mg regimen, and in four of seven on the 800-mg regimen. All five women monitored for at least 6 weeks became culture negative. There was no association between in vitro susceptibility of C. trachomatis to fleroxacin and outcome, with MICs being 4 to 8 migrograms/ml for almost all isolates tested. Among those with positive cultures for Ureaplasma urealyticum initially, the first follow-up cultures remained positive in 8 (29%) of 28 men and 8 (50%) of 16 women. Independent of culture results, men with nongonococcal urethritis receiving 800 mg of fleroxacin were significantly more likely to show a clinical response than men receiving 400 or 600 mg (93 versus 54%). Adverse events were frequent, often severe, and dose related....Continue Reading

References

Nov 1, 1978·The Journal of Infectious Diseases·W R BowieE R Alexander
Oct 1, 1989·Antimicrobial Agents and Chemotherapy·W R BowieP J Jewesson
Oct 1, 1985·Antimicrobial Agents and Chemotherapy·J S Wolfson, D C Hooper
Feb 1, 1986·Annals of Internal Medicine·J N WasserheitD A Eschenbach
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·E WeidekammD Dell
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·R A PustH Meier-Ewert
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·O Steele-Mortimer, H Meier-Ewert
Jan 1, 1988·Reviews of Infectious Diseases·H Halkin
Apr 17, 1987·JAMA : the Journal of the American Medical Association·A E WashingtonL L Sanders
Oct 1, 1980·The British Journal of Venereal Diseases·W R BowieH D Jones

❮ Previous
Next ❯

Citations

Apr 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A R Ronald, R W Peeling
Jan 1, 1993·International Journal of Antimicrobial Agents·W CullmannA Braunsteiner
Jul 1, 1994·International Journal of Antimicrobial Agents·R H RubinA J Fischman
Jun 9, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert C Owens, Paul G Ambrose
Jul 25, 2000·Sexually Transmitted Diseases·M R GoldenM E St Louis
Oct 1, 1989·Antimicrobial Agents and Chemotherapy·W R BowieP J Jewesson
Oct 1, 1993·Antimicrobial Agents and Chemotherapy·A J FischmanH W Strauss
Feb 7, 1991·The New England Journal of Medicine·D C Hooper, J S Wolfson
Jan 27, 2019·The Cochrane Database of Systematic Reviews·Carol Páez-CanroHernando G Gaitán
Jan 13, 2001·The Medical Clinics of North America·R C Owens, P G Ambrose

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.